Article
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.
The pharmacogenomics journal - 1 Aug 2015
Ray A, Tennakoon L, Keller J, Sarginson J E, Ryan H S, Murphy G M, Lazzeroni L C, Trivedi M H, Kocsis J H, DeBattista C, Schatzberg A F
Abstract excerpt
The hypothesis that allelic variation in the multidrug resistance-1 (MDR1 or ABCB1) gene encoding the P-glycoprotein (P-gp) blood-brain barrier efflux pump is associated with remission and side effects was tested in chronic major depression patients treated with P-gp substrates. In 83 patients from the REVAMP trial, frequency of and time to remission as well as side effects was tested among genotype groups at 6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.